FORM OF ELECTION AND LETTER OF TRANSMITTALBridgeBio Pharma, Inc. • November 6th, 2020 • Pharmaceutical preparations
This Form of Election Form and Letter of Transmittal (the “Election Form”) is being delivered in connection with the Agreement and Plan of Merger, dated October 5, 2020 (as amended from time to time, the “Merger Agreement”), by and among BridgeBio Pharma, Inc. (“BridgeBio”), Eidos Therapeutics, Inc. (“Eidos”), Globe Merger Sub I, Inc. (“Merger Sub I”) and Globe Merger Sub II, Inc. (“Merger Sub II”), and the Joint Proxy Statement/Prospectus (File No. 333-[•]) of BridgeBio and Eidos on Form S-4 filed on November 6, 2020, as amended, with the Securities and Exchange Commission (the “Joint Proxy Statement/Prospectus”). The Merger Agreement provides for the acquisition of the shares of common stock of Eidos (“Eidos common stock”) not held by BridgeBio or its subsidiaries through the following steps, on the terms and conditions set forth in the Merger Agreement: (i) Merger Sub I will merge with and into Eidos (the “initial merger”), with Eidos surviving the initial merger and (ii) immediatel
